Valuation: Glaukos Corporation

Market Cap 10.55B 9.42B 8.7B 7.88B 14.75B 1,001B 14.99B 105B 41.45B 525B 39.58B 38.74B 1,654B P/E 2026 *
-221x
P/E 2027 * 546x
Enterprise Value 10.37B 9.26B 8.56B 7.75B 14.51B 985B 14.75B 103B 40.76B 516B 38.92B 38.09B 1,626B EV / Sales 2026 *
15x
EV / Sales 2027 * 12.1x
Free-Float
96.38%
Yield 2026 *
-
Yield 2027 * -
1 day+1.24%
1 week+8.52%
Current month+8.95%
1 month+16.54%
3 months+17.58%
6 months+47.99%
Current year+58.43%
1 week 164.08
Extreme 164.085
179.7
1 month 146.38
Extreme 146.385
179.7
Current year 93.96
Extreme 93.96
191.62
1 year 73.16
Extreme 73.16
191.62
3 years 59.22
Extreme 59.22
191.62
5 years 33.33
Extreme 33.33
191.62
10 years 23.08
Extreme 23.075
191.62
Manager TitleAgeSince
Chief Executive Officer 65 31/12/2000
Director of Finance/CFO 56 31/03/2022
President 50 31/03/2022
Director TitleAgeSince
Chairman 65 30/12/2021
Director/Board Member 71 30/06/2014
Director/Board Member 57 30/06/2014
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Executive/Senior Manager

-1,527 0.0027%
25/09/26 Sell

Executive/Senior Manager

-1,615 0.0028%
16/09/26 Sell

Executive/Senior Manager

-1,457 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
+1.24%+8.52% - - 10.42B
Average +1.24%
Weighted average by Cap. +1.24%

Financials

2026 *2027 *
Net sales 692M 618M 571M 517M 967M 65.66B 983M 6.87B 2.72B 34.4B 2.6B 2.54B 108B 852M 761M 703M 637M 1.19B 80.92B 1.21B 8.46B 3.35B 42.4B 3.2B 3.13B 134B
Net income -51.86M -46.31M -42.78M -38.77M -72.53M -4.92B -73.73M -515M -204M -2.58B -195M -190M -8.13B 19.26M 17.2M 15.89M 14.4M 26.94M 1.83B 27.39M 191M 75.7M 958M 72.29M 70.75M 3.02B
Net Debt -175M -156M -144M -131M -245M -16.6B -249M -1.74B -687M -8.7B -656M -642M -27.42B -273M -244M -225M -204M -382M -25.9B -388M -2.71B -1.07B -13.57B -1.02B -1B -42.78B
Projected Income Statement - Annual - Glaukos Corporation
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
23/10/26 US$178.88 +1.24% 961,188
22/10/26 US$176.69 -0.09% 885,765
21/10/26 US$176.85 +1.97% 930,333
20/10/26 US$173.43 +3.88% 613,796
19/10/26 US$166.96 +1.29% 775,393
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Glaukos Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
178.88USD
Average target price
199.31USD
Spread / Average Target
+11.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Glaukos Corporation
  1. Stock Market
  2. Stocks
  3. GKOS Stock